Introduction
Thromboembolic disease has become one of the major causes of maternal mortality in Western communities (Jeffcoate and Tindall, 1965) . It is generally accepted that anticoagulant therapy is indicated in the non-pregnant patient for the treatment of venous thrombosis and pulmonary embolism (Barritt and Jordan, 1960; Thomas, 1965; O'Sullivan et al., 1968) and for prophylaxis after heart valve replacement (Duvoisin et al., 1967; Pansegrau et al., 1968) . In pregnancy the mortality and morbidity associated with these conditions is probably even higher; however, their treatment with anticoagulant drugs poses a number of unresolved questions.
Of the two available groups of anticoagulants, heparin is thought to be the more effective (O'Sullivan et al., 1968) and is safer for the fetus as it does not cross the placenta (Flessa et al., 1965) . Since it must be given parenterally, however, its long-term use is much less convenient than that of the oral anticoagulants. The latter drugs, on the other hand, have been shown to cross the placenta and to predispose to fetal haemorrhage, both experimentally (Quick, 1946; Kraus et al., 1949) and clinically (Quenneville et al., 1959; Finnerty and MacKay, 1962; Johnson and Greenwalt, 1965; Taylor, 1965; Villasanta, 1965a Villasanta, , 1965b Gilliland, 1966 ing pregnancy (Douglas, 1962; Johnson and Greenwalt, 1965; Villasanta, 1965b) . Examination of the available experimental and clinical evidence suggested to us that the incidence of fetal haemorrhage may not be increased unless the mother is given oral anticoagulants near term. An anticoagulant regimen based on this supposition was used in the treatment of 14 patients in 15 pregnancies. The purpose of this paper is to present the results of this series and to discuss the maternal and fetal problems associated with the use of anticoagulant drugs during pregnancy.
Methods
Coagulation tests were performed on maternal venous and on neonatal mixed cord blood. Whole-blood clotting-times were done by a modification of the Lee-White method. Estimation of prothrombin and kaolin partial thromboplastin times and assays of factors II, V, VII-X complex, VIII, and X and fibrinogen were performed by methods previously described (Cade et al., 1969) .
Anticoagulant Regimen.-The following therapeutic regimen was used: (1) patients with clinically severe or recurrent thromboembolism were treated with heparin for 10 to 14 days and then with an oral anticoagulant (warfarin) until 37 weeks' gestation; (2) patients with clinically minor single episodes of calf vein thrombosis or minor pulmonary embolism' were treated for 14 days with heparin only; (3) heparin alone was used after 37 weeks' gestation; and (4) when pregnancy was diagnosed in the first trimester, heparin was used until 13 weeks' gestation and was followed by oral anticoagulants when long-term therapy was indicated. Heparin was administered either by continuous intravenous infusion, and the dose regulated to maintain the whole-blood clotting-time between 20 and 30 minutes at all times or by intermittent 12-hourly subcutaneous injection (Calciparine) to produce a clotting-time of 15 to 20 minutes before the next injection. The dose of warfarin was regulated to maintain the onestage prothrombin time at two to two and a half times control levels.
Patients and Results
Fourteen patients were treated with anticoagulant drugs during 15 pregnancies (see Table) . Eleven had venous thrombosis, three of these also had pulmonary embolism; three had prosthetic heart valves; and one had mitral stenosis with pulmonary hypertension.
All 15 cases were given heparin and 10 received warfarin in addition. The mean duration of heparin therapy was 4.5 weeks (range 2 to 6 weeks) and of oral anticoagulant therapy 14 weeks (range 0 to 37 weeks). Two patients developed further thromboembolic complications while being treated 
Maternal Mortality and Morbidity
The mortality of antepartum thromboembolism has been reported to be about 150,, in untreated patients, but there has been only one death in over 100 reported cases given anticoagulants (Ullery, 1954; Finnerty and McKay, 1962; DeVita et al., 1965; Villasanta, 1965a) . Even allowing for possible selection bias, the available evidence would suggest that anticoagulant therapy significantly reduces mortality in antepartum thromboembolism. The value of long-term anticoagulant therapy in non-pregnant patients with prosthetic heart valves has been well established (Duvoisin et al., 1967; Pansergrau et al., 1968) , and it would be expected that the risk of systemic thromboembolism would be at least as great during pregnancy. In the present series of 15 cases (see Table) , there were two instances of further thromboembolism during anticoagulant therapy, but both were minor.
Anticoagulant Regimen
It is difficult to define a regimen of anticoagulant therapy during pregnancy that is safe, practical, and effective, and the approach outlined above is suggested as a reasonable compromise. thought that these patients were exposed to both local and general predisposing factors to thromboembolism for the duration of pregnancy (Quenneville et al., 1959; Johnson and Greenwalt, 1965: Gilliland, 1966 ).
In these patients and in those with prosthetic heart valves (Cases 1, 2, and 6) heparin was substituted for warfarin at 37 weeks' gestation in order to avoid exposure of the fetus to oral anticoagulants near delivery should premature labour occur. In fact one patient (Case 11) (Evans et al., 1968) . It is, however, known that this procedure does not always give protection from pulmonary embolism in the nonpregnant patient (Amador et al., 1968; O'Sullivan et al., 1968) and furthermore, that it is associated with some risk to both mother and fetus (Sibthorpe, 1955; DeVita et al., 1965; Taylor, 1965 (Quenneville et al., 1959; Finnerty and MacKay, 1962; Taylor, 1965) . On the other hand, the incidence of traumatic bleeding from extrauterine sites such as the episiotomy may be increased. Thus of the seven patients who had prolonged clotting-times at delivery (Cases 1, 2, 3, 4, 6, 7, and 9) , two developed small haematomata of the episiotomy (Cases 1 and 3 ). Anticoagulants were not thought to be a contributing factor to bleeding in the other two patients (Cases 7 and 13).
Fetal Haemorrhage
Oral anticoagulants are generally thought to be contraindicated during pregnancy because of the risk of fetal haemorrhage. This belief is based on both experimental and clinical findings. In animals, Quick (1946) and Kraus et al. (1949) found a very high incidence of fetal haemorrhage and death after giving coumarins to the mother. In both studies large doses were given until term, so that the fetuses were delivered at a tirre when their coagulation system was severely impaired.
Recent investigations from this department have suggested that the trauma of delivery may be an important contributing factor to fetal haemorrhage when coagulation is impaired by vitamin-K antagonists (Hirsh et al., 1970) . In this study all the fetuses of pregnant rabbits given warfarin until term were stillborn with widespread haemorrhage, while there was no fetal haemorrhage when delivery was performed by caesarean section just before term, despite severe depression of coagulation factors in both mother and fetuses. Furthermore, fetal bleeding did not occur when the warfarin was stopped a few days before term, so that the levels of fetal clotting-factors had returned to normal before delivery.
At first sight the reported clinical observations on the use of anticoagulants in pregnancy appear to be contradictory. Villasanta (1965b) reviewed the reported cases of antepartum thrombophlebitis treated with oral anticoagulants and concluded that these drugs should not be used during pregnancy because of the risk of fetal haemorrhage.
Re-evaluation of those case reports in which adequate details were available, however, suggested to us that oral anticoagulants may not increase the risk of fetal damage unless continued until term. Thus among the 10 patients reviewed by Villasanta (1965b) who were still receiving oral anticoagulants at the 40th week of gestation there were five instances of perinatal haemorrhage, of which four were fatal (two fetal and two neonatal). On the other hand, of the 13 fetal deaths in 47 cases given oral anticoagulants at an earlier stage of pregnancy, only one was clearly due to haemorrhage. Furthermore, Runge and Hartert (1954) and Mertz and Breitner (1956) were unable to find evidence of fetal haemorrhage when they gave coumarins to 12 women before they underwent legal abortion.
No fetal or neonatal haemorrhage was encountered in any of the 10 patients in this series who were treated with oral anticoagulants at some time during pregnancy. While the numbers are too small to reach a definite conclusion our findings also suggest that the risk from oral anticoagulants may not be high provided treatment with these drugs is stopped before delivery.
The available evidence, both clinical and experimental, indicates that depression of the vitamin-K-dependent coagulation factors in the fetus due to the placental passage of oral anticoagulant drug is reversible; however, the minimum time required for fetal coagulation factors to return to normal is not known. In Cases 1 and 2, in which oral anticoagulants had been given from before conception until 37 weeks' gestation, neonatal coagulation tests were normal at delivery. On the other hand, even when heparin produced a significant anticoagulant effect in the mother at delivery (Cases 1, 2, 3 The possibility that oral anticoagulants produce fetal morbidity and mortality by means other than depression of vitamin-K-dependent clotting-factors requires serious consideration. It is possible that the 12 non-haemorrhagic fetal deaths reviewed by Villasanta (1965b) and mentioned above were due to vitamin-K antagonists. Some of the patients, however, had severe pulmonary embolism, and fetal death has also been reported in association with untreated pulmonary embolism (Blum and Barre, 1957) . In addition, Runge and Hartert (1954) and Mertz and Breitner (1956) found no evidence of fetal damage in 12 women given coumarins between the second and fifth months of pregnancy before legal abortion. More recently nasal bone malformations have been reported in two cases where the mother was given warfarin in the first two months of pregnancy (Kerber et al., 1968) .
Four cases in our series (Nos. 1, 2, 11, and 14) were treated with anticoagulants during the first trimester, three with oral agents and one with heparin, with no evidence.of fetal damage. These numbers, however, are small and certainly do not exclude the possibility that oral anticoagulants can produce effects on the fetus other than depression of coagulation factors. Hence these drugs, and indeed any drugs that cross the placenta, should be given in pregnancy only when there are firm indications. This is particularly so in the first trimester, when the risk of teratogenetic effects is at its greatest. Because of this, our present policy is to instruct women on oral anticoagulant therapy to report at the first possibility of pregnancy. If this is confirmed, treatment with warfarin is stopped and heparin is used until about 13 weeks' gestation.
